CL2022002479A1 - Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas - Google Patents

Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas

Info

Publication number
CL2022002479A1
CL2022002479A1 CL2022002479A CL2022002479A CL2022002479A1 CL 2022002479 A1 CL2022002479 A1 CL 2022002479A1 CL 2022002479 A CL2022002479 A CL 2022002479A CL 2022002479 A CL2022002479 A CL 2022002479A CL 2022002479 A1 CL2022002479 A1 CL 2022002479A1
Authority
CL
Chile
Prior art keywords
therapy
nirogacestat
combination therapy
targeting bcma
bcma
Prior art date
Application number
CL2022002479A
Other languages
English (en)
Inventor
Webster Shearer Todd
Edris Badreddin
Original Assignee
Springworks Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Springworks Therapeutics Inc filed Critical Springworks Therapeutics Inc
Publication of CL2022002479A1 publication Critical patent/CL2022002479A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente descripción proporciona métodos para tratar el cáncer o la amiloidosis de cadena ligera en un sujeto que lo necesite, que comprenden administrar una terapia combinada que comprende una cantidad eficaz de la Forma A del dihidrobromuro de nirogacestat y una terapia dirigida al antígeno de maduración de linfocitos B (BCMA, por sus siglas en inglés) al sujeto y los usos de estas.
CL2022002479A 2020-03-13 2022-09-12 Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas CL2022002479A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062989372P 2020-03-13 2020-03-13

Publications (1)

Publication Number Publication Date
CL2022002479A1 true CL2022002479A1 (es) 2023-08-18

Family

ID=75396879

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002479A CL2022002479A1 (es) 2020-03-13 2022-09-12 Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas

Country Status (16)

Country Link
US (1) US20230121547A1 (es)
EP (1) EP4132515A1 (es)
JP (1) JP2023517243A (es)
KR (1) KR20230009873A (es)
CN (1) CN115916188A (es)
AR (1) AR121566A1 (es)
AU (1) AU2021236340A1 (es)
BR (1) BR112022018251A2 (es)
CA (1) CA3171267A1 (es)
CL (1) CL2022002479A1 (es)
CO (1) CO2022014388A2 (es)
IL (1) IL296075A (es)
MX (1) MX2022011258A (es)
PE (1) PE20230614A1 (es)
TW (1) TW202200132A (es)
WO (1) WO2021183934A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023064872A1 (en) * 2021-10-14 2023-04-20 Precision Biosciences, Inc. Combinations of anti-bcma car t cells and gamma secretase inhibitors
CA3239013A1 (en) * 2021-11-23 2023-06-01 Anantha Rajmohan MUTHUSAMY Solid state forms of nirogacestat salts
US11951096B2 (en) 2022-05-20 2024-04-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
US20230372301A1 (en) 2022-05-20 2023-11-23 Springworks Therapeutics, Inc. Treatments with nirogacestat
US20240148695A1 (en) 2022-05-20 2024-05-09 Springworks Therapeutics, Inc. Treatments with nirogacestat
WO2024025968A1 (en) * 2022-07-28 2024-02-01 Springworks Therapeutics, Inc. Treatment of multiple myeloma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149855B2 (en) * 2014-02-05 2018-12-11 The Trustees Of Columbia University In The City Of New York Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides
KR20180033232A (ko) * 2015-07-24 2018-04-02 온코트랙커 인코포레이티드 면역계 기능장애의 치료를 위한 감마 세크레타제 조절제
IL268349B1 (en) * 2017-02-17 2024-04-01 Hutchinson Fred Cancer Res Combination therapies for the treatment of BCMA-associated cancer and autoimmune disorders
WO2018201051A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) * 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
MX2020004568A (es) * 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
US11970542B2 (en) * 2017-11-08 2024-04-30 Fred Hutchinson Cancer Center Bispecific antibodies specific for treating hematological malignancies
WO2019143818A1 (en) * 2018-01-17 2019-07-25 Mingsight Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
CA3101340A1 (en) * 2018-05-24 2019-11-28 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
BR112020024351A2 (pt) * 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
US20220168417A1 (en) * 2019-04-10 2022-06-02 Glaxosmithkline Intellectual Property Development Limited Combination therapy with an anti bcma antibody and a gamma secretase inhibitor
CA3150424A1 (en) * 2019-08-09 2021-02-18 Pfizer Inc. Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Also Published As

Publication number Publication date
TW202200132A (zh) 2022-01-01
PE20230614A1 (es) 2023-04-14
AU2021236340A1 (en) 2022-09-29
CN115916188A (zh) 2023-04-04
CO2022014388A2 (es) 2023-02-16
EP4132515A1 (en) 2023-02-15
MX2022011258A (es) 2023-01-11
BR112022018251A2 (pt) 2022-11-08
WO2021183934A1 (en) 2021-09-16
AR121566A1 (es) 2022-06-15
CA3171267A1 (en) 2021-09-16
IL296075A (en) 2022-11-01
KR20230009873A (ko) 2023-01-17
US20230121547A1 (en) 2023-04-20
JP2023517243A (ja) 2023-04-24

Similar Documents

Publication Publication Date Title
CL2022002479A1 (es) Una terapia combinada con nirogacestat y una terapia dirigida a bcma y usos de estas
DOP2020000209A (es) Métodos para tratar cánceres y potenciar la eficacia de agentes terapéuticos para el redireccionamiento de células t
CO2017011197A2 (es) Terapia de combinación fgfr/pd-1 para el tratamiento del cancer
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2017002996A1 (es) Compuestos alqueno tetrasustituidos y su uso
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
CL2020002075A1 (es) Métodos para tratar el cáncer con anticuerpos anti-pd1.
CL2022002808A1 (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas
CO2024000588A2 (es) Composiciones y métodos para la inhibición de ras
MX2020004573A (es) Terapia de combinacion con agonistas de ox40 dirigidos.
PE20211915A1 (es) Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso
PE20120998A1 (es) Metodos para el tratamiento del cancer usando antagonistas de notch
CL2019000585A1 (es) Combinación de un anticuerpo anti-cd20, inhibidor pi3 kinase-delta y anticuerdo anti-pd-1 o anti-pd-l1 para el tratamiento de cánceres hematológicos.
PE20211266A1 (es) Metodos y composiciones para la dosificacion de celulas t con receptor de antigeno quimerico alogenicas
CO2021008665A2 (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
ECSP23019525A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
CL2022001717A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
BR112023006364A2 (pt) Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe
CL2021001635A1 (es) Tratamiento combinado para tumores sólidos con docetaxel y un inhibidor de cyp3a
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
CO2021004681A2 (es) Uso de reboxetina para el tratamiento de narcolepsia